Detalhe da pesquisa
1.
Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years.
Mult Scler;
28(10): 1576-1590, 2022 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35229668
2.
Survival analysis for AdVerse events with VarYing follow-up times (SAVVY): Rationale and statistical concept of a meta-analytic study.
Biom J;
63(3): 650-670, 2021 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33145854
3.
Quantitative assessment of adverse events in clinical trials: Comparison of methods at an interim and the final analysis.
Biom J;
62(3): 658-669, 2020 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31756032
4.
Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol;
18(4): 435-445, 2017 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28284557
5.
Feasibility of adding everolimus to carboplatin and paclitaxel, with or without bevacizumab, for treatment-naive, advanced non-small cell lung cancer.
Invest New Drugs;
32(1): 123-34, 2014 Feb.
Artigo
em Inglês
| MEDLINE
| ID: mdl-23579358
6.
Improving Data Collection in Pregnancy Safety Studies: Towards Standardisation of Data Elements in Pregnancy Reports from Public and Private Partners, A Contribution from the ConcePTION Project.
Drug Saf;
47(3): 227-236, 2024 Mar.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38114757
7.
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study.
Lancet;
378(9808): 2005-2012, 2011 Dec 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-22119496
8.
Survival analysis for AdVerse events with VarYing follow-up times (SAVVY)-estimation of adverse event risks.
Trials;
22(1): 420, 2021 Jun 29.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34187527
9.
Everolimus in advanced pancreatic neuroendocrine tumors: the clinical experience.
Cancer Res;
73(5): 1449-53, 2013 Mar 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-23436795
10.
Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer.
J Thorac Oncol;
7(10): 1594-601, 2012 Oct.
Artigo
em Inglês
| MEDLINE
| ID: mdl-22968184